TG Therapeutics, Inc. (TGTX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$55.99-1.27%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · TGTX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of USD, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 | Dec 2015 | Dec 2014 | Dec 2013 | Dec 2012 | Dec 2011 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenues | ||||||||||||||||
| Revenues | 799.5 | 616.3 | 329.0 | 233.7 | 2.8 | 6.7 | 0.2 | 0.2 | 0.2 | — | — | — | — | — | — | — |
| Total Revenues | — | — | — | — | 2.8 | 6.7 | 0.2 | 0.2 | 0.2 | — | — | — | — | — | — | — |
| Cost of Revenues | 140.9 | 100.7 | 38.5 | 14.1 | 0.3 | 0.8 | — | — | — | — | — | — | — | — | — | — |
| Operating Expenses & Income | ||||||||||||||||
| Selling, General & Admin | 296.5 | 232.0 | 154.3 | 122.7 | 95.5 | 128.1 | 107.9 | — | — | — | — | — | — | — | — | — |
| R&D Expenses | 225.8 | 160.2 | 94.3 | 76.2 | 125.4 | 222.6 | 165.9 | 154.2 | 159.4 | 102.5 | 69.2 | 47.7 | 40.1 | 13.7 | 21.0 | 0.3 |
| Operating Income | 136.3 | 123.3 | 41.9 | 20.6 | (218.3) | (344.8) | (273.6) | (169.1) | (174.4) | (118.7) | (79.0) | (63.2) | (55.7) | (23.0) | (26.9) | (0.9) |
| Earnings from Continuing Operations | ||||||||||||||||
| Interest Expense | — | 26.7 | 24.0 | 12.6 | 10.2 | 5.6 | 6.3 | 5.3 | — | — | — | 1.0 | 0.9 | 1.0 | 0.9 | 0.0 |
| Other Non-Operating Income / Expenses | (34.7) | (15.9) | (16.3) | (7.6) | (5.5) | (3.3) | (5.8) | (3.8) | 0.9 | 0.2 | 0.7 | 0.2 | (0.1) | 2.5 | 1.0 | — |
| Asset Writedown | — | — | — | — | — | — | — | — | — | — | — | 2.8 | 2.8 | 2.8 | — | — |
| EBT, Incl. Unusual Items | 101.6 | 107.4 | 25.6 | 13.1 | (223.8) | (348.1) | (279.4) | (172.9) | (0.2) | (0.1) | (78.3) | (62.9) | (55.8) | (20.5) | (25.9) | — |
| Income Tax Expense | (339.9) | (339.8) | 2.2 | 0.4 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.3 | — |
| Net Income | ||||||||||||||||
| Minority Interest | — | — | — | — | — | — | — | — | — | — | — | — | — | 0.0 | (8.1) | (0.0) |
| Net Income | 441.5 | 447.2 | 23.4 | 12.7 | (198.3) | (348.1) | (279.4) | (172.9) | (173.5) | (118.5) | (78.3) | (62.9) | (55.8) | (20.5) | (18.1) | (0.9) |
| Per Share | ||||||||||||||||
| Basic EPS | 3.11 | 3.10 | 0.16 | 0.09 | (1.65) | (2.63) | (2.42) | — | — | — | — | — | — | — | — | — |
| Diluted EPS | 2.81 | 2.77 | 0.15 | 0.09 | (1.65) | (2.63) | (2.42) | — | — | — | — | — | — | — | — | — |
| Revenue per Share | 5.08 | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Basic Weighted Avg Shares | 141.8 | 144.3 | 145.3 | 142.0 | 135.4 | 132.2 | 115.3 | — | — | — | — | — | — | — | — | — |
| Diluted Weighted Avg Shares | 157.3 | 161.4 | 160.3 | 148.5 | 135.4 | 132.2 | 115.3 | — | — | — | — | — | — | — | — | — |
| Supplemental | ||||||||||||||||
| EBITDA | — | 123.4 | 42.0 | 20.8 | (218.0) | (344.5) | — | — | — | — | — | — | — | — | — | — |
| EBIT | 136.3 | 123.3 | 41.9 | 20.6 | (218.3) | (344.8) | (273.6) | (169.1) | (174.4) | (118.7) | (79.0) | (63.2) | (55.7) | (23.0) | (26.9) | (0.9) |
| Effective Tax Rate | -334.5% | — | — | 3.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | -1.2% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.